Currently, several hormonal therapies are available to treat specific tumors such as androgen-dependent prostate cancer (e.g., enzalutamide) and human epidermal growth factor receptor 2 (HER2) positive breast cancers (e.g., tamoxifen). This evidence concerns the gene ERBB2 and breast carcinoma.